July 28, 2014 1:54 AM ET


Company Overview of Aerial BioPharma LLC

Company Overview

Aerial BioPharma LLC, a biopharmaceutical company, engages in drug development for central nervous system. The company focuses on developing biologics and small molecules for conditions that are affected by processes in the central nervous system. Aerial BioPharma LLC was founded in 2011 and is based in Morrisville, North Carolina.

9001 Aerial Center Parkway

Aerial Center Executive Park

Suite 110

Morrisville, NC 27703

United States

Founded in 2011





Key Executives for Aerial BioPharma LLC

Co-Founder and Chief Executive Officer
Co-Founder and Executive Vice President of Drug Development
Acting Chief Financial Officer
Senior Director of Chemistry and Manufacturing
Compensation as of Fiscal Year 2014.

Aerial BioPharma LLC Key Developments

Jazz Pharmaceuticals Announces Acquisition from Aerial BioPharma LLC of Rights to Late Stage Investigational Compound for Excessive Daytime Sleepiness

Jazz Pharmaceuticals plc and Aerial BioPharma, LLC announced that the companies have signed a definitive agreement under which Jazz Pharmaceuticals has acquired rights to ADX-N05, a novel compound in clinical development for the treatment of excessive daytime sleepiness in patients with narcolepsy. Under the agreement, a subsidiary of Jazz Pharmaceuticals has acquired worldwide development, manufacturing and commercial rights to ADX-N05, other than in certain countries in Asia where SK Biopharmaceuticals Co. Ltd. (SK) retains rights. Under the agreement, Aerial will receive an upfront payment of $125 million. Aerial and SK are eligible to receive milestone payments based on development, regulatory and sales milestones and tiered royalties based on potential future sales.

Aerial BioPharma LLC Presents at 2013 BIO International Convention, Apr-23-2013 03:00 PM

Aerial BioPharma LLC Presents at 2013 BIO International Convention, Apr-23-2013 03:00 PM. Venue: McCormick Place - Chicago Bulls Room, 2301 S. Lake Shore Drive, Chicago, IL 60616, United States.

Aerial BioPharma LLC Receives FDA Orphan Drug Designation for Narcolepsy Drug in Development

Aerial BioPharma LLC has received orphan drug designation for its narcolepsy drug in development. The U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan for ARL-N05 for the treatment of narcolepsy. In the United States, the prevalence of narcolepsy is estimated to be less than 200,000 qualifying as an orphan disease. The narcolepsy treatment will begin a Phase IIb clinical trial in September with results expected in mid-2013. The news from the FDA follows the successful completion of a Phase IIa study where N05 demonstrated highly statistically significant results on the primary and secondary efficacy endpoints in patients with narcolepsy.

Similar Private Companies By Industry

Company Name Region
Novartis Consumer Health, Inc. United States
Knoll Pharmaceutical Company United States
7 Oaks Pharmaceutical Corp. United States
Pradama Inc. United States
Presidio Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

January 13, 2014
Aerial BioPharma, LLC, ADX-N05

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Aerial BioPharma LLC, please visit www.aerialbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.